Decitabine combined with <scp>RDHAP</scp> regimen in relapsed/refractory diffuse large B cell lymphoma

Kong, Xiaoshuang; Zhang, Xudong; Ding, Mengjie; Feng, Xiaoyan; Meng, Di; Zhang, Lei; Fu, Xiaorui; Li, Ling; Li, Xin; Sun, Zhenchang; Yan, Jiaqin; Wang, Xinhua; Wu, Xiaolong; Chen, Qingjiang; Zhang, Mingzhi; Zhu, Linan

doi:10.1002/cam4.5615

Cited by 3 publications

(1 citation statement)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Some drugs have been confirmed to be effective in the treatment of DLBCL. Kong et al's clinical research confirmed the combined benefit of irditinib with the RDHAP regimen in the treatment of relapsed/refractory DLBCL [ 45 ]. Derek B Oien et al found that in heterologous transplantation models derived from DLBCL cell lines and patients, acatnib combined with AZD5153 demonstrated synergistic benefits [ 46 ].…”

Section: Discussionmentioning

confidence: 99%

Analyzing the involvement of diverse cell death-related genes in diffuse large B-cell lymphoma using bioinformatics techniques

Feng,

Zhang,

Kang

2024

Heliyon

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Analyzing the involvement of diverse cell death-related genes in diffuse large B-cell lymphoma using bioinformatics techniques

Feng,

Zhang,

Kang

2024

Heliyon

View full text Add to dashboard Cite

T Cells Spatially Regulate B Cell Receptor Signaling in Lymphomas through H3K9me3 Modifications

Britto,

Balasubramani,

Desai

et al. 2024

Adv Healthcare Materials

View full text Add to dashboard Cite

Activated B cell‐like diffuse large B‐cell lymphoma (ABC‐DLBCL) is a subtype associated with poor survival outcomes. Despite identifying therapeutic targets through molecular characterization, targeted therapies have limited success. New strategies using immune‐competent tissue models are needed to understand how DLBCL cells evade treatment. Here, synthetic hydrogel‐based lymphoma organoids were used to demonstrate how signals in the lymphoid tumor microenvironment (Ly‐TME) can alter B cell receptor (BCR) signaling and specific histone modifications, tri‐methylation of histone 3 at lysine 9 (H3K9me3), dampening the effects of BCR pathway inhibition. Using imaging modalities, T cells increased DNA methyltransferase 3A expression and cytoskeleton formation in proximal ABC‐DLCBL cells, regulated by H3K9me3. Expansion microscopy on lymphoma organoids revealed T cells increased the size and quantity of segregated H3K9me3 clusters in ABC‐DLBCL cells. Our findings suggest re‐organization of higher‐order chromatin structures that may contribute to evasion or resistance to therapy via the emergence of novel transcriptional states. Treating ABC‐DLBCL cells with a G9α histone methyltransferase inhibitor reversed T cell‐mediated modulation of H3K9me3 and overcame T cell‐mediated attenuation of treatment response to BCR pathway inhibition. This study emphasized the Ly‐TME's role in altering DLBCL fate and suggests targeting aberrant signaling and microenvironmental cross‐talk could benefit high‐risk patients.This article is protected by copyright. All rights reserved

show abstract

Decitabine combined with RDHAP regimen in relapsed/refractory diffuse large B cell lymphoma

et al. 2023

Self Cite

View full text Add to dashboard Cite

Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin lymphoma (NHL), accounting for approximately 30%-40% of cases. The current standard treatment is the R-CHOP regimen, although 30%-40% of patients relapse or develop refractory diseases. 1 Only 13% of these patients undergo high-dose chemotherapy followed by autologous stem cell transplantation (HDT-ASCT). 2 Patients with relapsed/refractory

show abstract

Decitabine combined with RDHAP regimen in relapsed/refractory diffuse large B cell lymphoma

Cited by 3 publications

References 37 publications

Analyzing the involvement of diverse cell death-related genes in diffuse large B-cell lymphoma using bioinformatics techniques

Analyzing the involvement of diverse cell death-related genes in diffuse large B-cell lymphoma using bioinformatics techniques

T Cells Spatially Regulate B Cell Receptor Signaling in Lymphomas through H3K9me3 Modifications

Decitabine combined with RDHAP regimen in relapsed/refractory diffuse large B cell lymphoma

Contact Info

Product

Resources

About